Danaher Corporation announced that its President and Chief Executive Officer, H. Lawrence Culp, Jr., will comment tomorrow on the Company's first quarter outlook at the Barclays Capital Industrial Select Conference in Miami, FL. Mr. Culp will communicate that the company's adjusted earnings per share is anticipated to be at or above the high end of the previous announced range of $0.77 to $0.82.

Mr. Culp stated: "We've been encouraged by the strong order activity and continuing margin performance through the first part of the quarter. In addition to improving end markets, the closing of the AB SCIEX transaction combined with our growth investments and new product introductions positions us well for the long term."

The Company expects that the AB SCIEX transaction will be accretive in 2010 by between $0.05 - $0.07 per share, excluding the impact of fair value adjustments and transaction costs of approximately $0.15 per share.

Danaher , based in Washington. D.C., is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. Our portfolio of premier brands is among the most highly recognized in each of the markets we serve. Driven by strong core values and a foundation provided by the Danaher Business System, our 47,000 associates serve customers in more than 125 countries and generated $11.2 billion of revenue in 2009. For more information please visit our website: www.danaher.com.

Statements in this release that are not strictly historical, including the statements regarding order activity, margin improvement, improving end markets, the impact of the AB SCIEX acquisition, growth investments and new product introductions, and expectations for 2010 and future periods, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking" statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the current uncertainty in the global economy and credit markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, our ability to successfully identify, consummate and integrate appropriate acquisitions, contingent liabilities relating to acquisitions, risks relating to potential impairment of goodwill and other long-lived assets, currency exchange rates, our compliance with applicable laws and regulations and changes in applicable laws and regulations, tax audits and changes in our tax rate, litigation and other contingent liabilities including intellectual property and environmental matters, risks relating to product defects and recalls, the impact of our debt obligations on our operations, pension plan costs, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, legislative health care reform and other changes in health care industry, labor matters, our relationships with and the performance of our channel partners, risks relating to man-made and natural disasters, our ability to achieve projected cost reductions and growth, and international economic, political, legal and business factors. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2008 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended October 2, 2009. These forward-looking statements speak only as of the date of this release and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

  Danaher Corporation                                                  
  Supplemental Reconciliation of Forecasted Diluted Earnings Per Share 
   to Prior Guidance                                                   
  For the Three Months Ended April 2, 2010 and Full Year 2010          
                                                                       
                                                                       
                                                                       
                                                   Current Guidance    
                                                   ----------------    
                                    Previous                           
                                    Guidance                           
                                      Three      Three       Twelve    
                                     Months      Months      Months    
                                      Ended      Ended       Ended     
                                    April 2,    April 2,   December 31,
                                      2010      2010 ***     2010 *    
                                    ---------  ---------  ------------- 
                                                                       
                                    Low   High             Low    High 
                                    ----  ----     -----   ---    ---- 
  Forecasted Adjusted Diluted                                          
   Earnings Per Share Prior to AB                                      
   SCIEX acquisition-related                                           
   costs                           $0.77 $0.82     $0.82  $3.86   4.16 
                                                                       
                                                                       
    AB SCIEX acquisition-related                                       
     costs **                          -     -     (0.09) (0.15) (0.15)
                                                                       
                                                                       
  Forecasted Diluted Earnings Per                                      
   Share (GAAP)                    $0.77 $0.82     $0.73  $3.71  $4.01 
                                   ===== =====     =====  =====  ===== 
                                                                       
  *  Based on the mid-point of a range of $0.05 to $0.07 accretion from 
     the acquisition before considering acquisition-related costs.

  ** Includes transaction costs associated with completion of the 
     acquisition (expensed in accordance with the adoption of the new 
     business combination accounting standard) and fair value adjustments 
     to acquisition-related inventory and deferred revenue balances 
     expected to be incurred in 2010 ("Acquisition Related Costs").    

  *** The Company believes it will be at or above the indicated guidance.

First Call Analyst:
FCMN Contact:

SOURCE: Danaher Corporation